(VRTX) Vertex Pharmaceuticals - Overview
Stock: CF Modulators, Gene Therapy, Pain Drug, Diabetes Cell Therapy, Kidney Pipeline
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 29.1% |
| Relative Tail Risk | -5.90% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.07 |
| Alpha | -11.63 |
| Character TTM | |
|---|---|
| Beta | 0.461 |
| Beta Downside | 0.160 |
| Drawdowns 3y | |
|---|---|
| Max DD | 29.07% |
| CAGR/Max DD | 0.57 |
Description: VRTX Vertex Pharmaceuticals January 27, 2026
Vertex Pharmaceuticals (NASDAQ: VRTX) is a Boston-based biotech that commercializes a portfolio of cystic fibrosis (CF) therapies-including TRIKAFTA/KAFTRIO, ALYFTREK, SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO-covering patients from birth to adulthood, and is expanding into sickle-cell disease, beta-thalassemia, acute pain, type 1 diabetes, myotonic dystrophy, and polycystic kidney disease through a pipeline of mRNA, small-molecule, and gene-editing candidates.
In FY 2023 Vertex generated $10.2 billion in revenue, a 12 % YoY increase driven largely by continued growth of its CF franchise, and reported Q4 2023 net income of $1.1 billion, reflecting a 15 % operating margin-both metrics placing it among the highest-margin biotech peers.
Key sector drivers include a projected 7 % CAGR for the global CF market (to >$15 billion by 2028) and the company’s recent Phase 3 data showing a 70 % reduction in vaso-occlusive crises for CASGEVY, positioning Vertex to capture a sizable share of the emerging sickle-cell therapy market. Collaborations with CRISPR Therapeutics, Moderna, and Entrada Therapeutics further diversify its R&D risk and open pathways to next-generation gene-editing platforms.
For a deeper quantitative assessment, you may want to explore Vertex’s metrics on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income: 3.68b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.13 > 0.02 and ΔFCF/TA 19.24 > 1.0 |
| NWC/Revenue: 51.98% < 20% (prev 54.89%; Δ -2.91% < -1%) |
| CFO/TA 0.15 > 3% & CFO 3.72b > Net Income 3.68b |
| Net Debt (-3.10b) to EBITDA (4.66b): -0.67 < 3 |
| Current Ratio: 2.36 > 1.5 & < 3 |
| Outstanding Shares: last quarter (257.6m) vs 12m ago -1.30% < -2% |
| Gross Margin: 86.28% > 18% (prev 0.86%; Δ 8542 % > 0.5%) |
| Asset Turnover: 49.78% > 50% (prev 47.76%; Δ 2.02% > 0%) |
| Interest Coverage Ratio: 348.4 > 6 (EBITDA TTM 4.66b / Interest Expense TTM 12.8m) |
Altman Z'' 6.22
| A: 0.25 (Total Current Assets 10.57b - Total Current Liabilities 4.48b) / Total Assets 24.86b |
| B: 0.50 (Retained Earnings 12.37b / Total Assets 24.86b) |
| C: 0.19 (EBIT TTM 4.46b / Avg Total Assets 23.55b) |
| D: 1.63 (Book Value of Equity 12.31b / Total Liabilities 7.54b) |
| Altman-Z'' Score: 6.22 = AAA |
Beneish M -2.94
| DSRI: 1.01 (Receivables 1.95b/1.75b, Revenue 11.72b/10.62b) |
| GMI: 1.00 (GM 86.28% / 86.11%) |
| AQI: 1.02 (AQ_t 0.45 / AQ_t-1 0.45) |
| SGI: 1.10 (Revenue 11.72b / 10.62b) |
| TATA: -0.00 (NI 3.68b - CFO 3.72b) / TA 24.86b) |
| Beneish M-Score: -2.94 (Cap -4..+1) = A |
What is the price of VRTX shares?
Over the past week, the price has changed by -0.24%, over one month by +1.51%, over three months by +11.79% and over the past year by +0.19%.
Is VRTX a buy, sell or hold?
- StrongBuy: 14
- Buy: 4
- Hold: 14
- Sell: 1
- StrongSell: 1
What are the forecasts/targets for the VRTX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 514.3 | 9.2% |
| Analysts Target Price | 514.3 | 9.2% |
| ValueRay Target Price | 527 | 11.9% |
VRTX Fundamental Data Overview February 07, 2026
P/E Forward = 24.0964
P/S = 10.0343
P/B = 6.8931
P/EG = 0.5801
Revenue TTM = 11.72b USD
EBIT TTM = 4.46b USD
EBITDA TTM = 4.66b USD
Long Term Debt = 1.83b USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 92.3m USD (from shortTermDebt, last fiscal year)
Debt = 1.83b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -3.10b USD (from netDebt column, last quarter)
Enterprise Value = 113.18b USD (117.63b + Debt 1.83b - CCE 6.29b)
Interest Coverage Ratio = 348.4 (Ebit TTM 4.46b / Interest Expense TTM 12.8m)
EV/FCF = 33.92x (Enterprise Value 113.18b / FCF TTM 3.34b)
FCF Yield = 2.95% (FCF TTM 3.34b / Enterprise Value 113.18b)
FCF Margin = 28.47% (FCF TTM 3.34b / Revenue TTM 11.72b)
Net Margin = 31.35% (Net Income TTM 3.68b / Revenue TTM 11.72b)
Gross Margin = 86.28% ((Revenue TTM 11.72b - Cost of Revenue TTM 1.61b) / Revenue TTM)
Gross Margin QoQ = 86.52% (prev 86.25%)
Tobins Q-Ratio = 4.55 (Enterprise Value 113.18b / Total Assets 24.86b)
Interest Expense / Debt = 0.18% (Interest Expense 3.30m / Debt 1.83b)
Taxrate = 16.62% (215.9m / 1.30b)
NOPAT = 3.72b (EBIT 4.46b * (1 - 16.62%))
Current Ratio = 2.36 (Total Current Assets 10.57b / Total Current Liabilities 4.48b)
Debt / Equity = 0.11 (Debt 1.83b / totalStockholderEquity, last quarter 17.32b)
Debt / EBITDA = -0.67 (Net Debt -3.10b / EBITDA 4.66b)
Debt / FCF = -0.93 (Net Debt -3.10b / FCF TTM 3.34b)
Total Stockholder Equity = 16.85b (last 4 quarters mean from totalStockholderEquity)
RoA = 15.60% (Net Income 3.68b / Total Assets 24.86b)
RoE = 21.81% (Net Income TTM 3.68b / Total Stockholder Equity 16.85b)
RoCE = 23.87% (EBIT 4.46b / Capital Employed (Equity 16.85b + L.T.Debt 1.83b))
RoIC = 22.07% (NOPAT 3.72b / Invested Capital 16.85b)
WACC = 7.50% (E(117.63b)/V(119.47b) * Re(7.61%) + D(1.83b)/V(119.47b) * Rd(0.18%) * (1-Tc(0.17)))
Discount Rate = 7.61% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -0.63%
[DCF Debug] Terminal Value 72.59% ; FCFF base≈3.34b ; Y1≈2.19b ; Y5≈999.5m
Fair Price DCF = 96.90 (EV 21.48b - Net Debt -3.10b = Equity 24.59b / Shares 253.7m; r=7.50% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: -18.70 | EPS CAGR: -6.10% | SUE: -0.91 | # QB: 0
Revenue Correlation: 98.48 | Revenue CAGR: 11.11% | SUE: 0.23 | # QB: 0
EPS next Quarter (2026-03-31): EPS=4.81 | Chg30d=-0.026 | Revisions Net=+0 | Analysts=11
EPS next Year (2026-12-31): EPS=20.16 | Chg30d=-0.080 | Revisions Net=-2 | Growth EPS=+9.3% | Growth Revenue=+8.5%